CALLICUTT JACK W 4

What Happened
Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics, was granted a total of 165,000 derivative awards on January 16, 2026: 65,000 stock options and 100,000 restricted stock units (RSUs). Both awards were reported at $0 acquisition price (i.e., no cash paid at grant). These are grants/awards (compensation/retention), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-01-16; Form 4 filed: 2026-01-21 (filed one business day late).
• Reported price: $0.00 for both awards (standard for grants).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Plan: Awards issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan (F1).
• Vesting: Options vest 25% on each of four dates (June 30, 2026; Dec 31, 2026; June 30, 2027; Dec 31, 2027) (F2). RSUs vest 100% on the earlier of Dec 31, 2026 or signing of a partnership agreement (F3) and convert one-for-one into common stock when vested (F4).
• Transaction type code: A = Award/Grant (derivative awards), not a buy/sell.

Context
These awards are typical executive compensation/retention instruments. Options only become valuable if the stock rises above the exercise price and vest per the schedule; RSUs convert to actual shares only upon vesting (and then could be sold). Because the filing was for grants rather than purchases/sales, it does not directly indicate immediate insider buying or selling activity. The one-business-day late filing reduces near-term transparency but does not change the economic terms of the awards.